Annotation Detail
Information
- Associated Genes
- ROS1
- Associated Variants
- ROS1 REARRANGEMENT ROS1 REARRANGEMENT
- Associated Disease
- lung non-small cell carcinoma
- Source Database
- CIViC Evidence
- Description
- An expansion cohort of a phase-1 Crizotinib study found a 72% objective response rate among 50 patients with ROS1 rearrangement. The study did not compare to patients without rearrangement that were treated with Crizotinib. Several different ROS1 fusion partners were identified, but no clinical differences in outcome were associated with the identity of the 5' partner.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/688
- Gene URL
- https://civic.genome.wustl.edu/links/genes/4941
- Variant URL
- https://civic.genome.wustl.edu/links/variants/269
- Rating
- 4
- Evidence Type
- Predictive
- Disease
- Lung Non-small Cell Carcinoma
- Evidence Direction
- Supports
- Drug
- Crizotinib
- Evidence Level
- B
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 25264305
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Crizotinib | Sensitivity | true |